Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-03-31

Clinical Trial Update: PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II) [NA]

View source ↗

Summary

Clinical trial PROMPT AF II compares PVI alone versus PVI with linear ablation for persistent atrial fibrillation; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Persistent Atrial Fibrillation | NA | Status: RECRUITING